Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease
Primary Purpose
Obesity, Cardiovascular Disease
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Lifestyle-based physical activity
Sponsored by
About this trial
This is an interventional prevention trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- Obese: BMI ≥30 kg/m2
- Lean (controls): BMI ≤ 25 kg/m2) age 14 to 18 years and Tanner stage matched
- Ability to understand and cooperate with the procedures
- Signed informed consent from subjects and parents
Exclusion Criteria:
- Medications such as Beta-adrenergic blockers, steroids and other drugs known to affect protein metabolism
- Heart disease
- Chronic liver disease
- Chronic renal disease
- Active malignancy
- Alcoholism or drug abuse
- Anemia
- Inter-current illness over the 7 days before the study
- Surgery in the past 3 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention
Control
Arm Description
12 weeks of lifestyle-based physical activity intervention
12 weeks of no intervention
Outcomes
Primary Outcome Measures
Protein turnover
Stable isotope mass spectrometry
Fractional synthesis rate of fibrinogen
Stable isotope mass spectrometry
Fibrinogen
Plasma concentration measured by nephelometry
Secondary Outcome Measures
Fat mass
Dual-energy X-ray absorptiometry (DEXA)
Fat free mass
Dual-energy X-ray absorptiometry (DEXA)
Full Information
NCT ID
NCT02613741
First Posted
November 19, 2015
Last Updated
October 13, 2022
Sponsor
Nemours Children's Clinic
1. Study Identification
Unique Protocol Identification Number
NCT02613741
Brief Title
Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease
Official Title
Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
January 2001 (Actual)
Primary Completion Date
January 2004 (Actual)
Study Completion Date
December 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nemours Children's Clinic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Since obesity and plasma fibrinogen levels are important CVD risk factors in the adults, and since childhood obesity is a major risk factor for adult obesity and also because it is not established whether or not this is due to an increase in the FSR of fibrinogen, the investigators set up the studies with the following specific aims:
To investigate the metabolism of fibrinogen and VLDL apoB-100, CVD risk factors, in childhood obesity by measuring their fractional synthetic rate (FSR) compared to lean age and sex matched controls
To determine the outcome of a three month non-pharmacological intervention (physical exercise combined with controlled diet) to reduce weight on the FSR of fibrinogen and apoB-100
To determine the relationship between FSR of fibrinogen and IL-6 in obese children and its potential implications on CVD before and after the non-pharmacological intervention
To determine other CVD risk factors, PAI-1 levels, D-Dimer concentration, homocysteine, insulin, free fatty acid, HDL & LDL cholesterol and blood pressure in response to weight reduction (as consequence of a combined program of diet and exercise).
Detailed Description
A. SPECIFIC AIMS:
Evidence from the literature suggests that:
childhood onset of obesity increases the risk of obesity and cardiovascular disease (CVD) in adulthood;
plasma fibrinogen and apolipoprotein B-100 (apoB-100) levels are elevated in obesity;
elevated levels of plasma fibrinogen and apolipoprotein B-100 (apoB-100) are major independent risk factors for CVD in adults;
raised plasma fibrinogen levels in obese children and/adolescents could be a major factor responsible for CVD morbidity and mortality in adulthood;
a low level of physical activity is associated with a high level of plasma fibrinogen in adults;
physical training and controlled diet have been proved to be non-pharmacological ways to improve hemostatic function in adults, thereby reducing heart disease risk. Despite these evidences the mechanism of these changes remain unclear. A better understanding of the mechanism of these changes will lead to more directed therapies to reduce these risk factors early in life.
The increased plasma concentrations of fibrinogen (and/or other proteins) is decided by the equilibrium between two dynamic processes in the body, namely, synthesis and degradation rates of these proteins. Therefore, elevated levels of fibrinogen must be a consequence of:
increased fibrinogen synthesis;
decreased fibrinogen degradation or
a contribution of both.
For designing effective therapies it is important to know, whether the increased concentration of plasma fibrinogen is due to increased synthesis or decreased degradation or both. Using stable isotope mass spectrometry techniques it is possible to measure the synthesis rates of proteins in vivo in humans. Yet until now there are no reports on the direct measurement of FSR of fibrinogen and/or apoB-100 in childhood obesity, important CVD risk factors. The direct measurement of degradation rates of proteins in vivo in humans, however, is not easily done. Few studies have reported changes in the concentrations of fibrinolytic markers such as plasminogen activator inhibitor-1 (PAI-1) and D-Dimer in obesity. This, however, accounts for only a small fraction of the elevated levels of plasma fibrinogen in childhood obesity. On the other hand recent preliminary results in three subjects from our lab show that fibrinogen synthesis rate is substantially higher (more than two times) in obese adolescent girls Vs lean controls (please see results under "Preliminary results" below). Pro-inflammatory cytokines, particularly interleukin-6 (IL-6), are known to play an important role in the regulation of acute phase reactive proteins associated with inflammation, including fibrinogen. A direct link between IL-6 and increased FSR of plasma fibrinogen in childhood obesity and CVD, however, is unknown. Also, other mechanisms involving insulin resistance and free fatty acid/albumin ratio are also equally plausible for the increased synthesis of fibrinogen in obesity and CVD. Therefore, it is important to understand and establish the relationship between increased FSR of fibrinogen and these regulating factors in this study for two reasons:
to better design effective therapies based on these results and
to further understand the pathophysiology of these changes in CVD and obesity.
The overall purpose of the proposed studies is therefore:
to expand on our preliminary data and establish the observation of increased fibrinogen synthesis rate (in three subjects) in childhood obesity
to understand the relationship between increased FSR of fibrinogen and changes IL-6, insulin and glucose levels and free fatty acid (FFA) levels and FFA/albumin ratio in obese vs lean children
to study the effect of a non-pharmacological intervention program for three months (12 weeks), that involves weight reduction due to exercise and controlled diet on fibrinogen, apoB-100 and other cardiovascular risk factors and their relationship to changes in IL-6 levels, insulin/glucose ratio (a measure of insulin resistance), FFA/albumin ratio.
The proposed grant will use in vivo stable isotope (non-radioactive) dilution techniques, to test the following hypothesis:
Hypotheses:
higher rates of synthesis of fibrinogen and apoB-100 contribute substantially to their elevated levels in obese children;
plasma fibrinogen and apoB-100 concentration and synthesis decrease by non-pharmacological intervention to reduce weight, that involves regular physical exercise and controlled diet;
IL-6 and/or insulin resistance are important mechanistic links between increased plasma fibrinogen FSR and increased CVD risk and obesity and
the non-pharmacological intervention program modulates other CVD risk factors such as PAI-1, D-Dimer, homocysteine, free fatty acids, insulin, glucose, HDL and LDL cholesterol levels and IL-6 concentrations along with fibrinogen synthesis.
Summary of Specific Aims
Since obesity and plasma fibrinogen levels are important CVD risk factors in the adults, and since childhood obesity is a major risk factor for adult obesity and also because it is not established whether or not this is due to an increase in the FSR of fibrinogen, the investigators set up the studies with the following specific aims:
To investigate the metabolism of fibrinogen and VLDL apoB-100, CVD risk factors, in childhood obesity by measuring their fractional synthetic rate (FSR) compared to lean age and sex matched controls
To determine the outcome of a three month non-pharmacological intervention (physical exercise combined with controlled diet) to reduce weight on the FSR of fibrinogen and apoB-100
To determine the relationship between FSR of fibrinogen and IL-6 in obese children and its potential implications on CVD before and after the non-pharmacological intervention
To determine other CVD risk factors, PAI-1 levels, D-Dimer concentration, homocysteine, insulin, free fatty acid, HDL & LDL cholesterol and blood pressure in response to weight reduction (as consequence of a combined program of diet and exercise).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Cardiovascular Disease
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
12 weeks of lifestyle-based physical activity intervention
Arm Title
Control
Arm Type
No Intervention
Arm Description
12 weeks of no intervention
Intervention Type
Other
Intervention Name(s)
Lifestyle-based physical activity
Intervention Description
Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
Primary Outcome Measure Information:
Title
Protein turnover
Description
Stable isotope mass spectrometry
Time Frame
12 weeks
Title
Fractional synthesis rate of fibrinogen
Description
Stable isotope mass spectrometry
Time Frame
12 weeks
Title
Fibrinogen
Description
Plasma concentration measured by nephelometry
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Fat mass
Description
Dual-energy X-ray absorptiometry (DEXA)
Time Frame
12 weeks
Title
Fat free mass
Description
Dual-energy X-ray absorptiometry (DEXA)
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Obese: BMI ≥30 kg/m2
Lean (controls): BMI ≤ 25 kg/m2) age 14 to 18 years and Tanner stage matched
Ability to understand and cooperate with the procedures
Signed informed consent from subjects and parents
Exclusion Criteria:
Medications such as Beta-adrenergic blockers, steroids and other drugs known to affect protein metabolism
Heart disease
Chronic liver disease
Chronic renal disease
Active malignancy
Alcoholism or drug abuse
Anemia
Inter-current illness over the 7 days before the study
Surgery in the past 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Babu Balagopal, PhD
Organizational Affiliation
Nemours Children's Clinic
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
14513074
Citation
Balagopal P, Bayne E, Sager B, Russell L, Patton N, George D. Effect of lifestyle changes on whole-body protein turnover in obese adolescents. Int J Obes Relat Metab Disord. 2003 Oct;27(10):1250-7. doi: 10.1038/sj.ijo.0802388.
Results Reference
result
PubMed Identifier
15756217
Citation
Balagopal P, George D, Patton N, Yarandi H, Roberts WL, Bayne E, Gidding S. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr. 2005 Mar;146(3):342-8. doi: 10.1016/j.jpeds.2004.11.033.
Results Reference
result
PubMed Identifier
16131584
Citation
Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents. J Clin Endocrinol Metab. 2005 Nov;90(11):6192-7. doi: 10.1210/jc.2004-2427. Epub 2005 Aug 30.
Results Reference
result
PubMed Identifier
17341558
Citation
Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007 May;92(5):1971-4. doi: 10.1210/jc.2006-2712. Epub 2007 Mar 6.
Results Reference
result
PubMed Identifier
18507721
Citation
Balagopal P, George D, Sweeten S, Mann KJ, Yarandi H, Mauras N, Vaughan DE. Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D-dimer and fibrinolytic balance to physical activity-based intervention in obese children. J Thromb Haemost. 2008 Aug;6(8):1296-303. doi: 10.1111/j.1538-7836.2008.03037.x. Epub 2008 May 26.
Results Reference
result
PubMed Identifier
20094040
Citation
Balagopal PB, Gidding SS, Buckloh LM, Yarandi HN, Sylvester JE, George DE, Funanage VL. Changes in circulating satiety hormones in obese children: a randomized controlled physical activity-based intervention study. Obesity (Silver Spring). 2010 Sep;18(9):1747-53. doi: 10.1038/oby.2009.498. Epub 2010 Jan 21.
Results Reference
result
PubMed Identifier
23415619
Citation
Lovely R, Hossain J, Ramsey JP, Komakula V, George D, Farrell DH, Balagopal PB. Obesity-related increased gamma' fibrinogen concentration in children and its reduction by a physical activity-based lifestyle intervention: a randomized controlled study. J Pediatr. 2013 Aug;163(2):333-8. doi: 10.1016/j.jpeds.2013.01.004. Epub 2013 Feb 14.
Results Reference
result
PubMed Identifier
34286837
Citation
Cosentino RG, Churilla JR, Josephson S, Molle-Rios Z, Hossain MJ, Prado WL, Balagopal PB. Branched-chain Amino Acids and Relationship With Inflammation in Youth With Obesity: A Randomized Controlled Intervention Study. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3129-3139. doi: 10.1210/clinem/dgab538.
Results Reference
derived
Learn more about this trial
Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease
We'll reach out to this number within 24 hrs